Teresa Kirisits
Psychiatric/Mental Health · Frankfort, INNPI 1619485786
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,351 of the $15,276 with a category attached, or 74.3%. 31 manufacturers reported payments, led by Avadel CNS Pharmaceuticals, LLC at 30.5% of the total. Reporting peaked in 2024 at $7,149 and has fallen 58.4% since, to $2,977 in 2025. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $43.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avadel CNS Pharmaceuticals, LLC$5K
- Harmony Biosciences LLC$2K
- Jazz Pharmaceuticals Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Axsome Therapeutics, Inc.$1K
- plus $3K from 25 others
What the payments were for
- Consulting fees$2,15014%
- Travel & lodging$1,2648%
- Food & beverage$11,35174%
- Education$5113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avadel CNS Pharmaceuticals, LLC | 29 | $4,653 |
| Harmony Biosciences LLC | 86 | $2,065 |
| Jazz Pharmaceuticals Inc. | 42 | $1,631 |
| Teva Pharmaceuticals USA, Inc. | 28 | $1,346 |
| AbbVie | 38 | $1,111 |
| Axsome Therapeutics, Inc. | 23 | $1,005 |
| Otsuka America Pharmaceutical, Inc. | 10 | $543 |
| Novo Nordisk | 6 | $443 |
| Idorsia Pharmaceuticals US Inc | 15 | $297 |
| Ironshore Pharmaceuticals Inc. | 11 | $278 |
| Alkermes, Inc. | 3 | $265 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $252 |
| Merck | 14 | $244 |
| Neurocrine Biosciences, Inc. | 11 | $206 |
| Corium, LLC | 2 | $147 |
| Supernus Pharmaceuticals, Inc. | 3 | $143 |
| Johnson & Johnson | 2 | $137 |
| Eisai Inc. | 5 | $95 |
| EMD Serono, Inc. | 1 | $81 |
| Amgen | 3 | $53 |
| Resmed Corp | 3 | $47 |
| Novartis | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Noven Therapeutics, LLC | 1 | $24 |
| UCB, Inc. | 1 | $23 |
| Indivior Inc. | 1 | $22 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,276 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 50 | $652,484 |
| XywavSodium,calcium,mag,pot Oxybate | 21 | $321,236 |
| IngrezzaValbenazine Tosylate | 12 | $115,632 |
| SunosiSolriamfetol Hcl | 36 | $28,573 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,215 |
| BelsomraSuvorexant | 16 | $13,026 |
| Modafinil | 98 | $9,548 |
| Armodafinil | 45 | $4,470 |
| Gabapentin | 185 | $4,385 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 113 | $3,213 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 45 | $2,987 |
| Ropinirole Hcl | 72 | $2,153 |
| Lisdexamfetamine Dimesylate | 12 | $1,574 |
| Methylphenidate Hcl | 24 | $1,116 |
| Zolpidem Tartrate | 137 | $1,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $2,065 | $652,48450 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $206 | $115,63212 claims |
| Axsome Therapeutics, Inc.Sunosi | $1,005 | $28,57336 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $36 | $13,21536 claims |
| MerckBelsomra | $244 | $13,02616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Frankfort
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.